Abstract:Background The definitive treatment for myocardial ischemia is reperfusion. However, reperfusion injury has the potential to cause additional reversible and irreversible damage to the myocardium. One likely candidate for a cardioprotection is adenosine. The present study aimed at investigating the effect of intravenous adenosine on clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).Methods Patients with STEMI within 12 hours from the onset of symptoms were randomized by 1:1:1 ratio to receive either adenosine 50 mu g(.)kg(-1.)min(-1) (low-dose group, n=31), or 70 mu g(.)kg(-1.)min(-1) (high-dose group, n=32), or saline 1 ml/min (control group, n=27) for three hours. Drugs were given to the patients immediately after the guide wire crossed the culprit lesion. Recurrence of no-reflow, TIMI flow grade (TFG) and TIMI myocardial perfusion grade (TMPG), and collateral circulation were recorded. The postoperative and preoperative ST segment elevation sum of 18-lead electrocardiogram (ECG) and their ratio (STsum-post/STsum-pre) were recorded, as well as the peak time and peak value of CK-MB enzyme. Serial cardiac echo and myocardial perfusion imaging were performed at 24 hours and 6 months post-stenting. The primary endpoint was left ventricular function, and infarct size. The secondary end-point was the occurrence of cardiac and non-cardiac death, non-fatal myocardial infarction, and heart failure.Results A total of 90 STEMI patients were studied. No-reflow immediately after stent procedure was seen in 11 (35.5%) patients in the control group, significantly different from 6.3% in the low-dose group or 3.7% in the high-dose group (both P=0.001). STsum-post/STsum-pre in the low-dose and high-dose groups was significantly different from the control group (low-dose group vs. control group, P=0.003 and high-dose group vs. control group, P=0.001), without a dose-dependent pattern (P=0.238). The peak value of CK-MB enzyme was significantly reduced in the high-dose group compared to the control group (P=0.024). Compared to the left ventricular ejection fraction (LVEF) in control group, LVEF in the low-dose group increased by 5.8% at 24 hours (P=0.012) and by 10.9% at 6 months (P=0.007), LVEF in the high-dose group increased by 9.5% at 24 hours (P=0.001) and by 10.0% at 6 months (P=0.001), respectively. Significant reduction of infarct size by 24.2% was detected in the high-dose group vs. low-dose or control groups (P=0.008). There was no significant difference regarding secondary endpoints at 6 months among the treated groups. Cardiac function by NYHA classification in both the low-dose and the high-dose groups was improved significantly (P=0.013, P=0.016).Conclusion Intravenous adenosine administration might significantly reduce the recurrence of no-reflow, with resultant improved left ventricular systolic function. High-dose adenosine was further associated with significant reduction of infarct size. Chin Med J 2012;125(10):1713-1719

[Effects of High Dose Glucose-Insulin-potassium Infusion on Myocardial Injury and Serum Sfas/ Sfasl Concentration in Acute Myocardial Infarction].

High-Dose Glucose-Insulin-Potassium Treatment Reduces Myocardial Apoptosis in Patients with Acute Myocardial Infarction

High-dose glucose-insulin-potassium has hemodynamic benefits and can improve cardiac remodeling in acute myocardial infarction treated with primary percutaneous coronary intervention: From a randomized controlled study

Effect of glucose-insulin-potassium infusion on myocardial damage due to percutaneous coronary revascularization

Glucose, insulin and potassium (GIK) during reperfusion mediates improved myocardial bioenergetics

Effects and Mechanisms of Glucose-Insulin-potassium on Post-Procedural Myocardial Injury after Percutaneous Coronary Intervention.

The impact of glucose-insulin-potassium infusion in acute myocardial infarction on infarct size and left ventricular ejection fraction [ISRCTN56720616]

Glucose-insulin-potassium Therapy in Patients with ST-segment Elevation Myocardial Infarction.

Myocardial Protection by Glucose–Insulin–Potassium in Moderate- to High-Risk Patients Undergoing Elective On-Pump Cardiac Surgery: A Randomized Controlled Trial

Urokinase Combined with Liposomal Alprostadil in the Treatment of Acute Myocardial Infarction

Effect of hypodermic injection of granulocyte colony-stimulating factor on cardiomyocyte apoptosis and fibrosis after myocardial ischemia-reperfusion in swine

Progress in Using Insulin for Protective Effects after Acute Myocardial Infarction

Cardioprotection by GSK-3 inhibition: role of enhanced glycogen synthesis and attenuation of calcium overload

Effective Glycaemic Control Critically Determines Insulin Cardioprotection Against Ischaemia/reperfusion Injury in Anaesthetized Dogs

Granulocyte colony-stimulating factor inhibits ischemia-reperfusion injury via PI3K/Akt signal pathway

Systemic glucose-insulin-potassium reduces skeletal muscle injury, kidney injury, and pain in a murine ischaemia-reperfusion model

Three Hours Continuous Injection of Adenosine Improved Left Ventricular Function and Infarct Size in Patients with ST-segment Elevation Myocardial Infarction.

Evaluation of Effects of Granulocyte-Colony Stimulating Factor on Left Ventricular Function by Delayed-Enhancement Myocardial Magnetic Resonance Imaging Analysis in Patients with Acute Myocardial Infarction

Comparison of the effects of placental growth factor and vascular endothelial growth factor on acute myocardial infarction

An auxiliary strategy of partial least squares regression in pharmacokinetic/pharmacodynamic studies: A case of application of guhong injection in myocardial ischemia/reperfusion rats

Postconditioning effect of granulocyte colony-stimulating factor is mediated through activation of risk pathway and opening of the mitochondrial KATP channels